A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma

Peng Liu, Ying Han, Shiyu Jiang, Xiaohui He, Yan Qin, Lin Gui, Shengyu Zhou, Liqiang Zhou, Jian Yang, Sheng Yang, Tingyu Wen, Yuankai ShiChinese 2019 · DOI

Abstract

In comparison to patients aged 61 to 69 years, those aged ≥70 years have poorer survival. Prolonged survival is obtainable with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)-like in elderly Chinese patients in all age groups, indicating that the R-CHOP-like regimen should be considered for this population, even for those aged 70 years or older.
BibTeX
@inproceedings{liu2019retrospective,
  author = {Peng Liu and Ying Han and Shiyu Jiang and Xiaohui He and Yan Qin and Lin Gui and Shengyu Zhou and Liqiang Zhou and Jian Yang and Sheng Yang and Tingyu Wen and Yuankai Shi},
  title = {{A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma}},
  booktitle = {Chinese},
  year = {2019},
  doi = {10.1097/cm9.0000000000000354},
}

Loading related content...

Figure